# Health Catalyst to Announce Fourth Quarter and Year End 2025 Operating Results and Host Conference Call on Thursday, March 12, 2026
Canonical URL: https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-fourth-quarter-and-year-end-2025-operating-results-a-9f57d051
Ticker: HCAT
Company: Health Catalyst
Source: Health Catalyst
Published: 2026-03-02 13:00 EST
## Summary

Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics...

## Article Body
Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and year end 2025 operating results on Thursday, March 12, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.

Conference Call Details

The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID “HCATQ425.” A live audio webcast will be available online at https://ir.healthcatalyst.com/ . A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst (Nasdaq: HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,100 organizations worldwide rely on Health Catalyst's offerings, including our cloud-based technology ecosystem, Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.

Health Catalyst Media Contact:

‍Kathryn Mykleseth Director of Public Relations and Communications ‍ media@healthcatalyst.com

Health Catalyst Investor Relations Contact:

Matt Hopper SVP of Finance and Head of Investor Relations ir@healthcatalyst.com
## Recent Company News
- 2026-06-16 20:05 EST — [Health Catalyst to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/HCAT/health-catalyst-to-participate-in-upcoming-investor-conference-70ce0f58) — Source: Health Catalyst
- 2026-06-04 13:03 EST — [Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation](https://biopharmsignal.com/news/HCAT/health-catalyst-to-divest-vitalware-for-147-million-accelerating-strategic-trans-3fdcad3f) — Source: Health Catalyst
- 2026-05-11 20:05 EST — [Health Catalyst Reports First Quarter 2026 Results](https://biopharmsignal.com/news/HCAT/health-catalyst-reports-first-quarter-2026-results-bc27d6b4) — Source: Health Catalyst
- 2026-05-01 12:00 EST — [Health Catalyst to Announce First Quarter 2026 Operating Results and Host Conference Call on Monday, May 11, 2026](https://biopharmsignal.com/news/HCAT/health-catalyst-to-announce-first-quarter-2026-operating-results-and-host-confer-a23ecc29) — Source: Health Catalyst
- 2026-04-30 13:27 EST — [Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors](https://biopharmsignal.com/news/HCAT/health-catalyst-appoints-steve-nelson-president-of-aetna-to-its-board-of-directo-59637695) — Source: Health Catalyst
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)